Recursion

💡 “It’s not a taller ladder, it’s an elevator.”

In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio

Anne Carpenter spoke at @mit.edu about the importance of #biology imaging in the age of #AI. Using phenotypic maps, she says, Recursion has “identified thousands of screenable image phenotypes & hundreds of potential therapeutics & launched multiple clinical trials.” www.youtube.com/watch?v=kP-G...

🚀 A new article from CURE looks at how open-source datasets & tools like Boltz-2 are “unlocking powerful capabilities once limited to Big Pharma,” allowing startups & researchers to “dramatically accelerate & de-risk R&D involved in discovering new medicines.” wewillcure.com/insights/the... #techbio

Using AI and Automation to Improve Outcomes in Infectious Diseases

In a new paper in @acs.org Infectious Diseases, Recursion scientists look at how #AI & automation are helping to tackle ongoing challenges in global public health by:
▪️ generating hypotheses
▪️ overcoming data scarcity
▪️ streamlining clinical trials

Read more: www.recursion.com/news/using-a...

At the AI x BIO Summit, hosted by Decoding Bio & NYSE, Recursion Chief R&D and Chief Commercial Officer Najat Khan spoke w/ @biotechtv.bsky.social
about how we’re addressing the high failure rate in drug discovery using data and AI.
👉 full conversation here: biotechtv.com/post/recursi... #TechBio

Join our (L)earnings Call on Tuesday, August 5.
Today Recursion announced that we will provide business updates and report our Q2 2025 financial results on Tues., Aug. 5, 2025 at 8am ET / 6am MT / 1pm BST.

👉 Submit questions: forms.gle/ciFX2KbLfkAv...

👉 Read more: ir.recursion.com/news-release...

“How do we tap the potential in these data sets that can truly unlock better trials for patients, reduce timelines, and improve the patient experience?” - Sid Jain, SVP of clinical development and data science at Recursion, in a new article in Clinical Leader. www.clinicalleader.com/doc/clinical...

#ThrowbackThursday: Bold bets, breakthroughs & bottlenecks in #AI drug discovery at #BIO. In June, Recursion chief R&D & chief commercial officer Najat Khan, PhD joined industry leaders to discuss the tangible progress that’s already been made leveraging data & AI-led approaches in drug discovery.

YouTube video by Recursion Act Boldly, With Integrity -- CEO Chris Gibson on the Recursion Mindset

Act boldly, with integrity. In a video for our internal Recursion University (RXU) series, co-founder & CEO Chris Gibson illustrates the importance of one of our core values – act boldly, with integrity. #mindset #culture #RXU
👉 www.youtube.com/shorts/hyfh7...

✨Live from #ICML!

Researchers from @valenceai.bsky.social – Recursion’s #AI research engine – had a great time sharing our #ML breakthroughs at ICML last week in posters & presentations.

👉 Keep up with all the latest research at Valence here: www.valencelabs.com

In an industry where over 90% of drug candidates fail, we are relentlessly working to find a better way. A new feature in @wired.com highlights the dedicated drug hunters at Recursion using #AI to find new ways to tackle complex diseases.
www.wired.com/story/artifi... 🧪 #TechBio

🚀 How #TechBio is transforming drug discovery with data, AI and compute. Erik Douglas, VP of Product at Recursion, will present onstage at Ai4 happening Aug. 11-13 at the MGM Grand in Las Vegas.
ai4.io/vegas/regist... #TechBio #AI #Ai4

Advancing full-stack #AI solutions. Sid Jain, SVP of Clinical Development & Data Science, discussed how Recursion is applying AI & technology to accelerate the discovery & development of new medicines in a webinar with Drug Discovery World.
www.ddw-online.com/webinar-how-... #TechBio 🧪

Check out our latest ML advances at #ICML2025!

🔹 We’ll be presenting:

📎 Paper 1: Phenom-2 foundation model

📎 Paper 2: New framework to enhance transcriptomics by distilling knowledge from microscopy images

📎 Workshop: SIM: Scaling Up Interventional Models (sites.google.com/view/sim-icm...)

Recursion today announced the acquisition of full rights to the REV102 program from Rallybio. REV102 is a potential first-in-class oral ENPP1 inhibitor for the rare genetic disorder Hypophosphatasia (HPP). Learn more: ir.recursion.com/news-release...

A new feature in @pharmaphorum.bsky.social gets behind the buzzwords to look at what’s needed – namely, data quality, team culture, and clinical execution – to truly shift to an AI-led approach to developing new #cancer drugs across the industry. 👉 pharmaphorum.com/deep-dive/bu...
#TechBio 🧪

🤖 This week, we’re letting the robots take over while the humans recharge during our company-wide summer holiday. See you next week!⛱️ 🌞

Beyond Boltz-2: Toward More Powerful Drug Discovery Tools

🚀 Accelerating Boltz-2 for more efficient structure-based hit discovery. Today, Recursion is open-sourcing its SynFlowNet-Boltz trainer to enable more efficient design of high-affinity binders needed for successful early-stage drug discovery. Learn more: www.recursion.com/news/beyond-... #TechBio 🧪

Why Big Pharma is increasingly working with #TechBio partners. Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD, speaks with Peter Lawson, a biotech analyst at Barclays. 👉 Watch the full webcast here: barclays.webcasts.com/starthere.js...

We had a great turnout for #MoML 2025.

Sponsored by Recursion & @valenceai.bsky.social, MoML convenes researchers from academia & industry to discuss how ML can address key scientific goals related to molecular modeling, molecular interactions & therapeutic design.

👉https://portal.ml4dd.com/ 🧪

2 weeks ago, Kelly Zalocusky, Senior Director of Computational Biology, joined a panel at London Tech Week to discuss “AI in Action.”

On June 24, she'll present at Discovery & Development Europe on “Unlocking Drug Discovery At Scale Through Lab Automation & AI." oxfordglobal.com/discovery-de...

Recursion cofounder & CEO Chris Gibson sat down with David Bearss, cofounder & CEO of Halia Therapeutics & host of the Good Medicine Podcast, to discuss the original Recursion pitch, the rise of #TechBio, and why he believes a massive sea change is coming soon.
👉 www.youtube.com/watch?v=0LaO...

Recursion has joined the Council for Responsible Use of AI in Clinical Trials, launched today from Advarra, along with leaders from Sanofi and Velocity Clinical Research, Inc., to drive responsible AI innovation in clinical R&D.
www.advarra.com/news/advarra... #clinicaltrials 🧪

Last week, Recursion CFO Ben Taylor spoke at the Goldman Sachs 46th Annual Healthcare Conference in Miami, discussing validation points for the Recursion Operating System, pipeline advances, and how we drive value from collaborations like Boltz-2.
👉 event.webcasts.com/viewer/event... #TechBio 🧪

Join us at #BIO25! On Tues., June 17, 1:45-2:45pm ET, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will present on the panel “Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and Bottlenecks.” convention.bio.org/program-1/co... #TechBio 🧪

On June 18 at the Molecular Machine Learning Conference (MoML) at MILA, Gabriele Corso, one of the lead researchers behind Boltz-2, will present more on this latest breakthrough in AI drug discovery alongside researchers from Valence.

👉 Learn more: portal.ml4dd.com #MOML2025

At GTC Paris, we shared the news that NVIDIA has released new kernels in cuEquivariance and an NVIDIA NIM microservice to further accelerate the training and inference of molecular AI models like Boltz-2.

And earlier this week, more than 400 people attended a Boltz-2 seminar in person at MIT. 🧵

At #GTCParis, we joined NVIDIA’s booth to showcase the model which approaches the accuracy of physics-based FEP calculations at >1,000x the speed. Boltz-2 benefited from our NVIDIA supercomputer for training/validation & scientific support from
@valenceai.bsky.social, our AI research team. 🧵

Open science, activated.

Since the release of Boltz-2 last Friday – the new open-source protein structure and protein binding affinity model from MIT & Recursion – we’ve been introducing the model to the broader community and the reception has been terrific. 🧵

YouTube video by Recursion New Open Source Model from MIT & Recursion Solves Major Hurdle in AI Drug Discovery

More on Boltz-2, the new open source AI model from MIT & Recursion capable of predicting protein binding affinity w/ unprecedented speed, scale & accuracy -- the 1st model to combine structure & binding affinity prediction, approaching FEP accuracy w/ 1000X the speed. www.youtube.com/watch?v=gRtr...